World Investment Advisors Sells 7,271 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

World Investment Advisors trimmed its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 66.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,716 shares of the biotechnology company’s stock after selling 7,271 shares during the quarter. World Investment Advisors’ holdings in Arrowhead Pharmaceuticals were worth $233,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada raised its stake in shares of Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock valued at $576,000 after acquiring an additional 10,496 shares during the last quarter. AQR Capital Management LLC bought a new position in Arrowhead Pharmaceuticals during the 1st quarter worth $514,000. Goldman Sachs Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the period. Empowered Funds LLC lifted its holdings in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after buying an additional 979 shares during the period. Finally, Focus Partners Wealth grew its position in shares of Arrowhead Pharmaceuticals by 1,339.5% in the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 15,123 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $74.11 on Tuesday. The business has a 50-day moving average price of $77.92 and a two-hundred day moving average price of $69.42. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $14.30 and a 1-year high of $87.83. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market cap of $10.44 billion, a P/E ratio of -34.47 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company had revenue of $73.74 million for the quarter, compared to the consensus estimate of $73.84 million. During the same period in the previous year, the business earned $2.75 EPS. The firm’s revenue was down 86.4% compared to the same quarter last year. As a group, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ARWR. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 1st. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $78.00 to $100.00 in a report on Tuesday, April 21st. Chardan Capital reissued a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 30th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Leerink Partners boosted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $87.27.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider owned 226,958 shares of the company’s stock, valued at $17,021,850. This trade represents a 4.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This represents a 7.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 26,065 shares of company stock valued at $1,912,662. 3.60% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.